Pharmacoeconomics:friend or foe?

Abstract

The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

Metadata

Item Type:	Article
Authors/Creators:	Drummond, M. https://orcid.org/0000-0002-6126-0944
Copyright, Publisher and Additional Information:	© The Authors, 2006. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details
Keywords:	COST-EFFECTIVENESS,RHEUMATOID-ARTHRITIS,INFLIXIMAB REMICADE(R),CLINICAL EXCELLENCE,NATIONAL INSTITUTE,DECISIONS,SWEDEN
Dates:	Published: November 2006
Institution:	The University of York
Academic Units:	The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York)
Depositing User:	Pure (York)
Date Deposited:	24 Nov 2016 10:14
Last Modified:	16 Oct 2024 12:09
Published Version:	https://doi.org/10.1136/ard.2006.058602
Status:	Published
Refereed:	Yes
Identification Number:	10.1136/ard.2006.058602
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:107938

Download

Pharmaco friend foe ARD 2006

Filename: Pharmaco_friend_foe_ARD_2006.pdf

Description: Pharmaco friend foe ARD 2006

CLICK TO DOWNLOAD

[thumbnail of Pharmaco friend foe ARD 2006]

CORE (COnnecting REpositories)

Pharmacoeconomics:friend or foe?

Abstract

Metadata

Download

Pharmaco friend foe ARD 2006

Export

Statistics